Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna(University Hospitals Birmingham NHS Foundation Trust), Mererid Evans(Velindre NHS Trust)

The Lancet

November 15, 2018

10.1016/s0140-6736(18)32752-1

Cited by 1,022

Related Papers

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

|International Journal of Radiation Oncology*Biology*Physics|2020|211

Diagnostic challenges and prognostic implications of extranodal extension in head and neck cancer: a state of the art review and gap analysis

|Frontiers in Oncology|2023|31

Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale

|Quality of Life Research|2021|17

Development and validation of an improved classification and risk stratification system for carotid body tumors: Multinational collaborative cohort study

|Head & Neck|2021|7